Abhijat Kitchlu | Onconephrology

Excellent update on MGRS Management by @SolosVJR and the pioneer of the field Dr. Leung

TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/41785046/

@PaulHannaMD @MCW_Nephrology @MedicalCollege Congrats, Paul!

Honored to receive the Excellence in Patient Experience Award for 2025 @MCW_Nephrology @MedicalCollege

Perspectives on Deprescribing Medications Among Patients Receiving Hemodialysis: A Qualitative Study @aabbaticchioMPH @onconeph @AnnaRGagliardi @marisabatt100 bit.ly/3MLdj8z

Pls join us for an amazing conference on “Radiation Oncology-What an Onconephrologist Needs to Know” by Dr Nelson and moderated by @SabineKaram6 February 20th Friday 12 PM EST

ASON is proud to partner with Brazilian Onconephrology division to organize the 1st International Onconephrology Symposium, featuring outstanding academic topics and an excellent lineup of speakers ✅Pls scan QR code to register Dr Torres, @kdjhaveri @ShrutiGkidney @onconeph

Amazing talk on eGFR estimation in cancer patients by @onconeph today for Nephrology grand rounds @StanfordNeph - practical yet based on cutting edge data in this rapidly evolving field! @onconephsociety

Thank you @onconephsociety for the wonderful recognition. Truly honored to have served as Social Media Chair and grateful for the trust and support🙏🙏 @SabineKaram6 @PAmarapurkar @rc_oncneph @onconeph @HerrmannMd @kdjhaveri @ShrutiGkidney @ArashRashidi14 @UTHealthSANeph

Perspectives on Deprescribing Medications Among Patients Receiving Hemodialysis: A Qualitative Study @aabbaticchioMPH @onconeph @AnnaRGagliardi @marisabatt100 bit.ly/3MLdj8z

📣 Thrilled to share our review article on “Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies and Management.” @KidneyMed A collaborative effort between talented members of the @onconephsociety First authored by @SwethaKanduriMD @PAmarapurkar @SabineKaram6 @VelezNephHepato @kdjhaveri kidneymedicinejournal.org/article/S2590-…

Read this #RedJournal article about a prospective phase 2 trial of renal SBRT demonstrating modest decline in renal function following treatment and excellent cancer control rates @r_glicksman @JA_Helou @UroOncMD @RHamiltonUrol @aleberlin2 @onconeph @radmedPM @UofTDRO @UHN_Research tinyurl.com/rjglicksman

Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis academic.oup.com/ckj/advance-ar…

Looking forward to meeting all @AfricanAFRAN members and learning about “Paraneoplastic Glomerulopathies” in the upcoming Clinical Nephrology Webinar, December 3rd at 7 pm Eastern African Time, 6 pm Cairo time.

Population-based data on AKI in patients receiving immune checkpoint inhibitors, including outcomes with re-challenge. Work led by Dr. Phil Blanchette. @ICESOntario @onconephsociety @UofTNephrology @NephrologyatUHN

Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors–related AKI doi.org/10.1093/ndt/gf…

Happening now: 1st International Onconephrology Symposium in Mexico 🇲🇽 hosted by @ABCcentromedico . @onconephsociety is very grateful for the warm reception by the hospital leadership, oncologists, and nephrologists led by Dr. Jacobo Kelber. His words regarding ASON were extremely generous. Super excited for the future of our societies.

Immune checkpoint inhibitor–associated nephritis: treatment standard 🆓 access: doi.org/10.1093/ndt/gf…

Thanks @ISNkidneycare @PAmarapurkar @SabineKaram6 for letting Dr @onconeph and I share some insights from the recently published Positions Statements on GFR assessment and ICI-AKI from the @onconephsociety . Check out the recorded webinar 👇🏽 @MayoClinicNeph

GFR Assessment in Cancer Patients @ISNeducation @ISNkidneycare @onconephsociety with @onconeph @PAmarapurkar @SabineKaram6

Current criteria for Cisplatin Eligibility can lead to suboptimal estimation of kidney function and to suboptimal dosing